Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, HER2-negative metastatic breast cancer. Phase 2 results reveal median ...

“Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evaluating the efficacy and safety of investigational patritumab deruxtecan ...

FDA has approved vepdegestrant (VEPPANU), the first PROTAC therapy, for adults with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy progression. In VERITAC-2, vepde ...

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase ...

—There was no significant difference in invasive disease-free survival between patients with human epidermal growth factor receptor 2-positive (HER2+) T1micN0 breast cancer who were and were not ...